AI Terminal
ALLERGY THERAPEUTICS PLC
Remuneration Information • Feb 14, 2025
7477_dirs_2025-02-14_0cc484ae-d5b5-4248-bc7a-5a4cc79d4c01.html
Remuneration Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0936X
Allergy Therapeutics PLC
14 February 2025
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Group")
Grant of Options
14 February 2025 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that on 13 February 2025 it granted share option awards to key members of Allergy Therapeutics' management team including certain of its persons discharging managerial responsibilities ("PDMRs").
The Board has granted options to encourage long-term value creation for the Company's shareholders, and so that the individuals identified as key people to lead the business into the future are appropriately incentivised in a manner that aligns with the interests of the Group's stakeholders.
Vesting is conditional on the satisfaction of performance criteria over a three year period. The vesting of any share options is subject to a share price threshold. So long as this share price threshold is exceeded, vesting of 70 per cent. of the award is subject to EBITDA performance and vesting of 30 per cent. of the award is subject to regulatory performance targets.
The following awards have been made in accordance with the Group LTIP:
| Name | Title | Number of share options granted | Resultant number of share options held | Performance period | Vesting Date | Exercise price | Number of Ordinary Shares held |
| M anuel Llobet | Chief Executive Officer | 7,517,637 | 17,168,300 | 3 years commencing 1 July 2024 | 30 June 2027 | £0.001 | 5,001,200 |
| Shaun Furlong | Chief Financial Officer | 3,405,573 | 7,215,097 | 3 years commencing 1 July 2024 | 30 June 2027 | £0.001 | 1,507 |
The number of Ordinary Shares stated above is the maximum number that could be issued to each PDMR upon full satisfaction of the performance conditions attached to the awards.
The Group's Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate having regard to overall Company performance and wider stakeholder experience.
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").
- ENDS -
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker/Rory Sale
Nigel Birks/Tamar Cranford Smith - Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com .
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations
1
Details of the persons discharging managerial responsibilities / person closely associated
a)
Name
Manuel Llobet
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Allergy Therapeutics plc
b)
LEI
213800PQ7AHK7KGVOE23
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of 0.1 pence each
Identification code
GB00B02LCQ05
b)
Nature of the transaction
Grant of options
c)
Price(s) and volume(s)
| Exercise Price per share | Volume | |
| £0.001 | 7,517,637 |
d)
Aggregated information
- Aggregated volume
- Price
See 4c) above
e)
Date of the transaction
06 February 2025
f)
Place of the transaction
Outside a trading venue
1
Details of the persons discharging managerial responsibilities / person closely associated
a)
Name
Shaun Furlong
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Allergy Therapeutics plc
b)
LEI
213800PQ7AHK7KGVOE23
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of 0.1 pence each
Identification code
GB00B02LCQ05
b)
Nature of the transaction
Grant of options
c)
Price(s) and volume(s)
| Exercise Price per share | Volume | |
| £0.001 | 3,405,573 |
d)
Aggregated information
- Aggregated volume
- Price
See 4c) above
e)
Date of the transaction
06 February 2025
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGPUPAPUPAPGW